Approach for cancer risk estimation of acrylamide in food on the basis of animal cancer tests and in vivo dosimetry.
The question about the contribution from acrylamide (AA) in food to the cancer risk in the general population has not yet had a satisfactory answer. One point of discussion is whether AA constitutes a cancer risk through its genotoxic metabolite, glycidamide (GA), or whether other mechanism(s) could be operating. Using a relative cancer risk model, an improvement of the cancer risk estimate for dietary AA can be obtained by estimation of the genotoxic contribution to the risk. One cornerstone in this model is the in vivo dose of the causative genotoxic agent. This paper presents an evaluation, according to this model, of published AA cancer tests on the basis of in vivo doses of GA in rats exposed in the cancer tests. The present status regarding data with importance for an improved estimation of the contribution from GA to the cancer risk of AA, such as in vivo doses measured in humans, is discussed.
Törnqvist
Margareta
M
margareta.tornqvist@mk.su.se.
Paulsson
Birgit
B
Vikström
Anna C
AC
Granath
Fredrik
F
D020106:Acrylamide / Q000008:administration & dosage / Q000032:analysis* / Q000633:toxicity*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004326:Drinking; D005260:Female; D005506:Food Contamination / Q000032:analysis*; D006454:Hemoglobins / Q000737:chemistry; D008297:Male; D009369:Neoplasms / Q000139:chemically induced*; D051381:Rats; D011916:Rats, Inbred F344; D012306:Risk
D006454:Hemoglobins; D020106:Acrylamide